CAMBRIDGE, Mass., Jan. 16 /PRNewswire/ -- Cytel, Inc. announced today that clinical research and business development executive Irving Dark has accepted the role of Vice President of Cytel Clinical Research Services. Mr. Dark brings to Cytel 15-years of management experience guiding drug, biologic and medical device products successfully through the development process as well as growing commercial clinical research organizations.
In his new position, Mr. Dark will head and drive the growth of Cytel’s cutting-edge clinical trial design and implementation services to the biopharmaceutical industry.
Prior to joining Cytel, Mr. Dark was Vice President, Business Development and Operations for Veristat, Inc. During his tenure he established and oversaw the company’s Data Management, Project Management, and Business Development departments. Mr. Dark was integrally involved with Veristat’s Corporate Compliance activities to ensure adherence with regulatory and GCP guidelines, and was instrumental in the company’s oncology and influenza contracts, and the Acambis smallpox vaccine program.
Previously, Mr. Dark held several key positions at full-service trial leader PAREXEL, rising from statistical programming management to overseeing the planning and conduct of phase 1, 2, and 3 global clinical trials.
“Irving’s experience in trial management and his knowledge of the clinical development needs of the biopharmaceutical industry are ideally suited to growing Cytel’s innovative clinical research services” said Ranganath Nayak, Chief Executive Officer of Cytel.
“Cytel has an impressive track record delivering innovative solutions to the biopharmaceutical industry,” said Irving Dark. “Cytel’s experience designing innovative clinical trials and its advanced analytical capabilities differentiate our trial services from those offered by traditional CRO’s. I am delighted to be joining the management team at such an exciting time for the company.”
About Cytel
Celebrating its 20th anniversary, Cytel Inc. is a leading provider of clinical trial consulting services, specialized statistical software, and outsourced clinical study reports for the biopharmaceutical, medical device, academic, and research institute markets. Cytel’s validated trial designs and implementation services reduce development time and costs while increasing the probability of clinical success. Cytel Inc. is headquartered in Cambridge, MA, with facilities in Philadelphia, PA and Pune, India.
CONTACT: Michael Weitz, Marketing Director of Cytel Inc., +1-617-661-2011,
mike@cytel.com
Web site: http://www.cytel.com/
